LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

World-First Urine Test Uses ‘Zombie’ Cell Proteins for Early Lung Cancer Detection

By LabMedica International staff writers
Posted on 10 Dec 2024
Print article
Image: World-first urine test for lung cancer picks out ‘zombie’ cells (Photo courtesy of Shutterstock)
Image: World-first urine test for lung cancer picks out ‘zombie’ cells (Photo courtesy of Shutterstock)

Lung cancer has a poor prognosis for many patients because symptoms often do not appear until the disease has spread to other parts of the body or throughout the lungs. Now, researchers have developed a novel urine test for the early detection of lung cancer. This test, the first of its kind, identifies ‘zombie’ cells, which may signal the initial stages of the disease. The goal is that early detection through this simple urine test could lead to earlier treatment interventions, improving patient outcomes and survival rates.

The research conducted at the University of Cambridge (Cambridge, UK) aims to provide an affordable, easy-to-use sensor that uses urine samples to detect lung cancer before it progresses. This new urine test focuses on spotting the disease early, offering doctors the ability to detect it before it fully develops. The scientists focused on proteins released by senescent cells—also known as ‘zombie’ cells, which are alive but no longer capable of dividing or growing. These cells can cause tissue damage by altering their surrounding environment, making it conducive to the development of cancer cells. The test is designed to detect these ‘zombie’ cells, as their presence in the body can be an early indicator of potential cancer development.

Although these senescent cells are not entirely dead, they accumulate in tissues and alter their environment in ways that facilitate the uncontrolled growth of cancerous cells. Researchers have developed an injectable sensor that interacts with proteins from zombie cells, releasing a compound that can be easily detected in the urine, signaling their presence. In preclinical testing with mice, the team has shown that the urine test is effective. The process begins with an injection of the sensor, which binds to the target proteins. Once the sensor is cleaved by the protein, a smaller part travels to the kidneys, where it is filtered and excreted through the bladder into the urine.

The second part of the test involves the use of a silver solution, which was once used in traditional photography, to change the color of the urine. By monitoring the urine's color after the sensor injection, researchers can determine if zombie cells are present in the lungs, potentially indicating early pathological changes that could lead to cancer. This technique offers the possibility of identifying lung cancer months or even years before symptoms appear. In some cases, this early detection could lead to cures without the need for surgery. The test could also offer a more affordable alternative to scans, which are currently used to detect lung cancer earlier. As the research team progresses into the final stages of pre-clinical validation, they are also exploring the use of this technology for detecting other types of cancer, including breast cancer, pancreatic cancer, and melanoma.

“We have almost completed a functional urine test to detect ‘zombie' cells in lung cancer, which will spot cancer earlier and avoid the need for invasive procedures, but this test does have potential for other cancers,” said Professor Ljiljana Fruk from the University of Cambridge. “Developing more efficient cancer treatments requires earlier detection and better therapies, but also work with other disciplines for a more holistic view of the disease, which is an essential part of my research.”

Related Links:
University of Cambridge

Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Lyme Disease Test
Lyme IgG/IgM Rapid Test Cassette
New
Respiratory Bacterial Panel
Real Respiratory Bacterial Panel 2

Print article

Channels

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Deliver Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: Schematic illustration of the chip (Photo courtesy of Biosensors and Bioelectronics, DOI: https://doi.org/10.1016/j.bios.2025.117401)

Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples

Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.